Capricor Therapeutics Announces Intent to File Biologics License ...
WEB18 hours ago · Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S ...
Capricor Therapeutics Announces Intent to File Biologics
WEB18 hours ago · 212.896.1204. Capricor Company Contact: AJ Bergmann, Chief Financial Officer. [email protected]. 858.727.1755. Industry: Website: -BLA to be Supported by Existing and Natural History Cardiac ...
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel …
WEBJun 28, 2024 · Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD).
Capricor Therapeutics Shares Rise in Premarket on Plans to File ...
WEB17 hours ago · Capricor Therapeutics shares rose in premarket trading Tuesday after the company said it plans to file a biologics license application for Deramiocel, its Duchenne muscular dystrophy ...
Capricor Therapeutics Signs Binding Term Sheet with Nippon …
WEBSep 17, 2024 · Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy.
Capricor Therapeutics Announces Pre-BLA Meeting with FDA for Deramiocel …
WEBJun 25, 2024 · Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD).
Capricor Therapeutics Announces for the Treatment of
WEBJun 25, 2024 · Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S....
Capricor’s cell therapy shows three year benefit in DMD patients
WEBJul 1, 2024 · Capricor Therapeutics has announced its deramiocel cell therapy continues to be safe and effective after three years for Duchenne muscular dystrophy (DMD). The Phase II (NCT03406780) three-year open-label extension (OLE) study showed that deramiocel led to a 47% slowing of disease in skeletal muscle in patients with DMD. The trial, involving 12 ...
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel …
WEBJun 28, 2024 · Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S...
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel …
WEBJun 28, 2024 · The HOPE-2 OLE study continues to show a favorable safety profile for long-term treatment of deramiocel. These data will be shared at this year’s Parent Project Muscular Dystrophy (PPMD) 30th ...
- Some results have been removed